[{"orgOrder":0,"company":"Micreos Human Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"NETHERLANDS","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"XZ.700","moa":"Cell wall","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Micreos Human Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Micreos Human Health \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Micreos Human Health \/ Not Applicable"},{"orgOrder":0,"company":"Micreos Human Health","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"NETHERLANDS","productType":"Large molecule","year":"2021","type":"Funding","leadProduct":"XZ.700","moa":"Cell wall","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Micreos Human Health","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0.040000000000000001,"dosageForm":"Topical","sponsorNew":"Micreos Human Health \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Micreos Human Health \/ Undisclosed"},{"orgOrder":0,"company":"Micreos Human Health","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"NETHERLANDS","productType":"Large molecule","year":"2022","type":"Financing","leadProduct":"XZ.700","moa":"","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Micreos Human Health","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0.02,"dosageForm":"","sponsorNew":"Micreos Human Health \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Micreos Human Health \/ Undisclosed"},{"orgOrder":0,"company":"Micreos Human Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"XZ.700","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Micreos Human Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Micreos Human Health \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Micreos Human Health \/ Not Applicable"},{"orgOrder":0,"company":"Micreos Human Health","sponsor":"Northway Biotechpharma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"LITHUANIA","productType":"Enzyme","year":"2025","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Micreos Human Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Micreos Human Health \/ Micreos Human Health","highestDevelopmentStatusID":"4","companyTruncated":"Micreos Human Health \/ Micreos Human Health"}]

Find Clinical Drug Pipeline Developments & Deals by Micreos Human Health

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : The parternship aims to develop scalable cGMP production processes for Micreos' biologic therapeutic MEndoB. It is the first-in-class dual-active domain targeted medicine to treat Atopic Dermatitis.

                          Product Name : Undisclosed

                          Product Type : Enzyme

                          Upfront Cash : Undisclosed

                          March 04, 2025

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Dermatology

                          Highest Development Status : Preclinical

                          Recipient : Northway Biotechpharma

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          02

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : MEndoC (XZ.700) is a world-class endolysin platform, as a topical treatment of the inflammatory skin symptoms associated with CTCL. Studies have shown that aggressive antibiotic treatment inhibits proliferation of malignant T-cells and disease activity.

                          Product Name : MEndoC

                          Product Type : Large molecule

                          Upfront Cash : Not Applicable

                          March 07, 2023

                          Lead Product(s) : XZ.700

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : Proceeds includes the clinical development of XZ.700 for endolysins against staphylococci (including MRSA) for Bloodstream Infections, Atopic Dermatitis, Diabetic Foot Ulcers and Cutaneous T-cell Lymphoma, a type of skin cancer associated with presence o...

                          Product Name : XZ.700

                          Product Type : Large molecule

                          Upfront Cash : Undisclosed

                          October 25, 2022

                          Lead Product(s) : XZ.700

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : $24.5 million

                          Deal Type : Financing

                          blank

                          04

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : This funding round will help Micreos accelerate its clinical development programs for atopic dermatitis, diabetic (MRSA) wounds and bloodstream infections, based on its pharmaceutical lead compounds, XZ.700 and SP.800.

                          Product Name : XZ.700

                          Product Type : Large molecule

                          Upfront Cash : Undisclosed

                          September 30, 2021

                          Lead Product(s) : XZ.700

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : $37.1 million

                          Deal Type : Funding

                          blank

                          05

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : Micreos Human Health has enrolled the first patients in a Phase I/IIa, randomized, double-blind, placebo-controlled, parallel treated dose-ranging study to assess the safety and efficacy of XZ.700 in patients with mild to moderate atopic dermatitis.

                          Product Name : XZ.700

                          Product Type : Large molecule

                          Upfront Cash : Not Applicable

                          September 22, 2020

                          Lead Product(s) : XZ.700

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank